Results | In 2017, a total of 110 experts responded from approximately 1100 listserv members (Table) . Actual and preferred use of natamycin and voriconazole in 2007 and 2017 are displayed in the Figure. Use of natamycin did not change (mean change, 0.0%; 95% CI, −5.9% to 5.9%; P > .99). Use of voriconazole increased by 12.0% (95% CI, −1.9% to 26.0%; P = .09). Natamycin as the preferred treatment increased by 19.9% (95% CI, 5.7%-34.2%; P = .006), and voriconazole decreased by 30.5% (95% CI, −45.3% to −16.0%; P < .001). In 2017, natamycin was indicated by 70 respondents (70.7%) (95% CI, 60.7%-79.4%) as the preferred treatment for ulcers caused by Fusarium species and by 43 (43.4%) respondents (95% CI, 33.5%-53.8%) as the preferred treatment for ulcers caused by Aspergillus species; voriconazole was indicated by 13 respondents (13.1%) (95% CI, 7.2%-21.4%) as the preferred treatment for ulcers caused by Fusarium species and 33 respondents (33.3%) (95% CI, 24.2%-43.5%) as the preferred treatment for ulcers caused by Aspergillus species.
Discussion | Choice of voriconazole as the preferred treatment for filamentous fungal keratitis decreased substantially in surveys conducted before and after MUTT I. However, ever use of voriconazole increased, possibly reflecting increased availability over time. In vitro results before MUTT I suggest that voriconazole would be effective for the treatment of fungal keratitis. 5, 6 In the 2007 survey, although voriconazole was the most commonly selected preferred treatment, many respondents indicated that more evidence was needed to guide treatment choices. 4 The MUTT I result was driven primarily by ulcers caused by Fusarium, which had the worst response to voriconazole. Actual use was measured by asking participants if they had ever used the treatment, and preferred use was measured by asking participants about their preferred treatment in an ideal situation in which cost, availability, and other concerns were not issues. 
